Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)
Clinical trial NCT01220648 · COMPLETED
Trial details
- NCT number
- NCT01220648
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-04-01
- Primary completion
- 2014-01-01
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.